The score is driven primarily by improving financial performance in 2025 (profit and free cash flow rebound with manageable leverage) and strong technical momentum (price above key moving averages with positive MACD). This is tempered by cyclical earnings/cash-flow variability, a modest valuation/income profile (P/E ~16.5 and ~1% yield), and earnings-call risks around regulatory uncertainty, near-term demand timing, and project/working-capital pressures.
Positive Factors
Market leadership in crop nutrition
Yara's long-established, vertically integrated fertilizer business supplies essential crop nutrients worldwide. Its product breadth (urea, ammonium nitrate, NPK, specialty fertilizers) plus digital farming and distribution reach creates durable demand exposure and resilience versus niche competitors.
Rebound in cash generation
A clear 2025 operating cash flow and free cash flow rebound shows the company can convert cyclical upcycles into meaningful liquidity. Sustained cash generation underpins the dividend policy, funds maintenance and growth CapEx, and provides flexibility for M&A or buybacks when cycles permit.
Manageable leverage and sizable equity
Moderate net debt and a large equity base provide balance-sheet optionality. This structural financial strength supports a predictable dividend framework, ability to absorb cyclical downturns, and capacity to fund prioritized projects without immediate need for dilutive financing.
Negative Factors
Cyclical earnings and cash-flow volatility
Profitability and cash conversion swing materially with fertilizer price and demand cycles. This structural volatility complicates long-term return predictability, increases stress on coverage metrics in weak years, and forces conservative capital allocation despite healthy balance-sheet capacity.
Large project cost and timing risk
The prioritized U.S. decarbonized ammonia project is capital intensive and exposed to construction and inflationary pressures. Cost overruns or delays would tie up cash, raise leverage or defer returns, and could crowd out other investments or shareholder distributions over multiple years.
Regulatory & external supply risks
Uncertainty around CBAM implementation and large, unpredictable export flows from China create structural upside and downside to European pricing. These external policy and supply shocks can erode margins and cash flow irrespective of Yara's operating execution, raising through-cycle risk.
Yara International (YARIY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.93B
Dividend Yield1.16%
Average Volume (3M)2.32K
Price to Earnings (P/E)15.2
Beta (1Y)0.42
Revenue Growth7.55%
EPS Growth34.28%
CountryUS
Employees16,624
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)0.58
Shares Outstanding509,451,260
10 Day Avg. Volume0
30 Day Avg. Volume2,323
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.38
Price to Sales (P/S)1.33
P/FCF Ratio21.74
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit4.28
Enterprise Value/Ebitda5.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.33
Revenue Forecast (FY)$15.68B
Yara International Business Overview & Revenue Model
Company DescriptionYara International ASA is a global leader in crop nutrition and a key player in the agricultural sector. Founded in Norway in 1905, the company specializes in the production and distribution of nitrogen-based fertilizers, as well as providing sustainable crop nutrition solutions. Yara operates in various segments, including fertilizers, crop protection, and digital farming, with a commitment to sustainability and innovation to enhance agricultural productivity worldwide.
How the Company Makes MoneyYara International generates revenue primarily through the sale of fertilizers, particularly nitrogen-based products, which are essential for crop growth. The company operates a revenue model based on the production and distribution of its core products, including urea, ammonium nitrate, and other specialty fertilizers. Key revenue streams include direct sales to farmers, agricultural distributors, and retail markets. Additionally, Yara invests in research and development to offer precision farming solutions, integrating digital tools that help farmers optimize their crop yields and resource use. Significant partnerships with agricultural organizations, research institutions, and sustainability initiatives also bolster its market presence and contribute to its earnings through collaborative projects and innovations in crop nutrition.
Yara International Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Apr 24, 2026
Earnings Call Sentiment Neutral
The call balanced clear commercial and operational strengths (strong Q4 Europe demand, production uptime, tight global nitrogen market, disciplined capital allocation and carbon position) against notable near‑term and medium‑term risks (CBAM political uncertainty, Q1 seasonality/stocking effects, NPK premium pressure, working capital build, and cost/timing risk on a major U.S. decarbonization project). Management’s tone was cautiously constructive: confident on market fundamentals and execution but circumspect about regulatory and project cost risk.
Q4-2025 Updates
Positive Updates
Strong Q4 Europe Demand and Price Momentum
Yara reported strong Q4 sales in Europe driven largely by customer and importer positioning ahead of CBAM (effective Jan 1), which contributed to price increases across products in Q4.
Deliveries Ahead Year‑over‑Year
Deliveries were approximately 7% ahead as of end‑December versus the prior year, leaving roughly half of seasonal demand still to be purchased heading into spring.
High Urea Export Prices and Tight Global Market
U.S. Gulf urea pricing near $500/ton is attracting imports and contributing to a globally tight nitrogen market; Chinese export volumes rose ~5 million tonnes in 2025, yet global supply‑demand remained tight.
Strong Plant Uptime and Production
Yara runs facilities continuously where margins are positive; management reports very strong uptime and higher production productivity, contributing to slightly higher sales and modest inventory build.
Capital Allocation and Growth Priority — U.S. Projects
Yara reiterated a capital framework with ~USD 1.2 billion annual CapEx guidance, prioritizing U.S. ammonia projects (including Air Products partnership) and energy/efficiency investments tied to decarbonization.
Balance Sheet/Cash Policy Flexibility
Net debt is below the stated range, supporting the company’s dividend policy (target ~50% cash dividend of net income) and creating optionality for buybacks or accretive investments.
Carbon & Emissions Positioning
Yara holds roughly 6 million ETS credits in the bank (covering expected needs out to ~2029), and many of Yara’s European plants have CO2 intensities below import benchmarks, giving a relative advantage under CBAM.
Maintenance CapEx Guidance
Maintenance/scheduled CapEx for 2026 is higher (~USD 200 million more vs 2025) but still within the communicated range of ~USD 700–850 million, reflecting a few larger turnarounds and some phasing.
Negative Updates
CBAM Political Uncertainty
While CBAM is in force (impacting Q4 pricing), a proposed legislative amendment (Paragraph 27a) to allow temporary suspension has created political uncertainty; outcome requires European Parliament approval and remains unpredictable.
Q1 Demand Uncertainty After Q4 Pre‑Buying
Because of significant pre‑buying in Q4 in Europe, management flagged a slower start to Q1 and dependence on spring field activity — causing uncertainty around timing of purchases and near‑term volumes.
Pressure on NPK Premiums
NPK premiums were pressured (notably in Asia/China/Thailand), causing an estimated negative EBITDA impact of approximately USD 20–30 million in the quarter versus the prior year.
Working Capital Buildup and Free Cash Flow Sensitivity
Seasonal working capital rose materially in recent quarters (partly price‑driven as receivables/inventory values increased), adding near‑term pressure on free cash flow; release depends on seasonal sales and price stability.
Air Products Project Cost and Timing Risk
The U.S. decarbonized ammonia project faces cost inflation and construction market pressures; management provided no update to prior cost ranges and acknowledged material uncertainty around final capex (previously discussed NOK 8–9 billion band by others).
Farmer Affordability and Demand Risk
High fertilizer prices are pressuring farmer economics (example: modeled optimal nitrogen for wheat ~4% lower vs prior year), creating potential downside to demand if grain prices and affordability remain weak.
Exposure to External Supply Shocks — China/Imports
Potential resumption/scale of Chinese urea exports (consultant baselines referenced ~6 million tonnes for future export windows) and import dynamics (EU imported ~2.2 million tonnes urea in Q1 last year) add volatility and downside risk to pricing and margins.
Company Guidance
Management guided that deliveries were about 7% ahead at end‑December versus last year with roughly half the seasonal demand still to be bought (the EU imported ~2.2 Mt of urea in Q1 last year), noting short‑term market drivers such as U.S. Gulf urea at ~$500/t, India’s 1.5 Mt tender and Chinese exports having risen ~5 Mt in 2025 (consultant baselines cited ~6 Mt for 2026). They said 2026 maintenance CapEx is ~USD 200m higher versus 2025 and sits in the upper part of their maintenance range (USD 700–850m/year), with total CapEx run‑rate around USD 1.2bn in the coming years; the Air Products project remains within previously stated ranges (NOK 8–9bn) but no new update was given. Working capital is seasonal (build into spring then release) and Q4 price strength lifted receivables and caused a modest inventory build; NPK premium pressure hit roughly $20–30m in Q4. Yara reported holding about 6 million ETS allowances (covering needs through ~2029), reiterated a 50% cash dividend policy, and confirmed there are no special turnaround plans materially different to prior years.
Yara International Financial Statement Overview
Summary
Financials show a clear 2025 rebound (revenue up ~3.9% YoY, net income up to ~$1.37B from near break-even in 2024) and stronger cash generation (2025 OCF ~$1.89B; FCF ~$0.96B). Balance sheet leverage is moderate and stable (debt ~$4.0–$4.3B; sizable equity), but earnings and cash flow remain meaningfully cyclical, limiting confidence in through-cycle stability.
Income Statement
66
Positive
Revenue rebounded in 2025 to $15.6B (up ~3.9% YoY) after a down 2024, showing demand/price cyclicality typical of agricultural inputs. Profitability improved meaningfully in 2025 with net income jumping to ~$1.37B from near break-even in 2024, indicating strong operating leverage when the cycle turns. The main weakness is volatility: 2022 was exceptionally strong, followed by a sharp earnings reset in 2023–2024, which lowers confidence in through-cycle margin stability.
Balance Sheet
72
Positive
Leverage looks manageable and fairly stable, with total debt around $4.0–$4.3B across the period and debt-to-equity around ~0.49–0.61 (where provided). Equity is sizable ($8.7B in 2025), supporting balance-sheet resilience, and assets have remained broadly steady. The key risk is that returns on equity have been highly cyclical—very strong in 2022 but extremely low in 2023–2024—suggesting profitability, not balance-sheet capacity, is the swing factor for credit/coverage comfort.
Cash Flow
69
Positive
Cash generation is solid in absolute terms: operating cash flow improved to ~$1.89B in 2025 from ~$1.29B in 2024, and free cash flow rose to ~$0.96B (up ~35.6% YoY). However, cash flow has been uneven (notably weaker free cash flow in 2024 versus 2023), and prior metrics indicate periods where cash conversion versus accounting earnings was not consistently strong. Overall, the company appears capable of producing healthy cash in favorable conditions, but the trajectory is cyclical rather than steadily compounding.
Breakdown
Dec 2025
Dec 2024
Dec 2023
Dec 2022
Dec 2021
Income Statement
Total Revenue
15.62B
13.81B
15.43B
23.90B
16.62B
Gross Profit
4.42B
3.68B
3.34B
6.55B
4.48B
EBITDA
3.12B
1.41B
1.47B
4.83B
2.58B
Net Income
1.37B
14.00M
48.00M
2.78B
449.00M
Balance Sheet
Total Assets
17.14B
14.99B
16.03B
17.98B
17.27B
Cash, Cash Equivalents and Short-Term Investments
913.00M
317.00M
447.00M
908.00M
350.00M
Total Debt
4.18B
4.05B
4.23B
4.22B
4.33B
Total Liabilities
8.39B
7.99B
8.46B
9.38B
10.15B
Stockholders Equity
8.72B
6.99B
7.55B
8.59B
7.10B
Cash Flow
Free Cash Flow
956.00M
248.00M
1.15B
1.47B
597.00M
Operating Cash Flow
1.89B
1.29B
2.29B
2.39B
1.41B
Investing Cash Flow
-906.00M
-1.08B
-1.20B
-509.00M
-874.00M
Financing Cash Flow
-392.00M
-401.00M
-1.52B
-1.23B
-1.50B
Yara International Technical Analysis
Technical Analysis Sentiment
Positive
Last Price17.97
Price Trends
50DMA
22.60
Positive
100DMA
20.63
Positive
200DMA
19.61
Positive
Market Momentum
MACD
0.80
Positive
RSI
70.15
Negative
STOCH
90.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YARIY, the sentiment is Positive. The current price of 17.97 is below the 20-day moving average (MA) of 24.50, below the 50-day MA of 22.60, and below the 200-day MA of 19.61, indicating a bullish trend. The MACD of 0.80 indicates Positive momentum. The RSI at 70.15 is Negative, neither overbought nor oversold. The STOCH value of 90.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for YARIY.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 18, 2026